Radioimmunotherapy of ovarian cancer

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Radioimmunotherapy (RIT) is a new therapeutical approach where radiolabeled monoclonal antibodies (M Ab) against tumor-associated antigens are administered to treat tumor lesions. Ovarian cancer is one of the most promising fields for RIT. This paper gives an overview of some biodistribution studies in animal models and in patients with radiolabeled anti-ovarian cancer M Abs, and defines the main criteria which should be considered to plan a clinical trial of RIT in ovarian cancer. As regards the clinical results, the published outcome of various trials and the experience of the National Cancer Institute of Milan are summarized. Even if the number of patients involved in these clinical studies of RIT is too small to provide conclusive indications about its role in the management of ovarian cancer, the preliminary results from qualified groups show its potential in this disease despite the current problems that limit clinical application (above all, the instability of the radiolabeled linkage, the immunogenicity of murine antibodies, the poor absolute tumor radiolabel uptake and the bone marrow toxicity).

Original languageEnglish
Pages (from-to)187-191
Number of pages5
JournalInternational Journal of Biological Markers
Volume8
Issue number3
Publication statusPublished - 1993

Fingerprint

Radioimmunotherapy
Ovarian Neoplasms
Tumors
Toxicity
National Cancer Institute (U.S.)
Bone
Animals
Neoplasm Antigens
Monoclonal Antibodies
Antigens
Neoplasms
Animal Models
Antibodies
Bone Marrow
Clinical Trials

ASJC Scopus subject areas

  • Biochemistry
  • Immunology

Cite this

Radioimmunotherapy of ovarian cancer. / Crippa, F.

In: International Journal of Biological Markers, Vol. 8, No. 3, 1993, p. 187-191.

Research output: Contribution to journalArticle

@article{12fbdaef6e4e445cb7f4bfd3fdf9a726,
title = "Radioimmunotherapy of ovarian cancer",
abstract = "Radioimmunotherapy (RIT) is a new therapeutical approach where radiolabeled monoclonal antibodies (M Ab) against tumor-associated antigens are administered to treat tumor lesions. Ovarian cancer is one of the most promising fields for RIT. This paper gives an overview of some biodistribution studies in animal models and in patients with radiolabeled anti-ovarian cancer M Abs, and defines the main criteria which should be considered to plan a clinical trial of RIT in ovarian cancer. As regards the clinical results, the published outcome of various trials and the experience of the National Cancer Institute of Milan are summarized. Even if the number of patients involved in these clinical studies of RIT is too small to provide conclusive indications about its role in the management of ovarian cancer, the preliminary results from qualified groups show its potential in this disease despite the current problems that limit clinical application (above all, the instability of the radiolabeled linkage, the immunogenicity of murine antibodies, the poor absolute tumor radiolabel uptake and the bone marrow toxicity).",
author = "F. Crippa",
year = "1993",
language = "English",
volume = "8",
pages = "187--191",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing Srl",
number = "3",

}

TY - JOUR

T1 - Radioimmunotherapy of ovarian cancer

AU - Crippa, F.

PY - 1993

Y1 - 1993

N2 - Radioimmunotherapy (RIT) is a new therapeutical approach where radiolabeled monoclonal antibodies (M Ab) against tumor-associated antigens are administered to treat tumor lesions. Ovarian cancer is one of the most promising fields for RIT. This paper gives an overview of some biodistribution studies in animal models and in patients with radiolabeled anti-ovarian cancer M Abs, and defines the main criteria which should be considered to plan a clinical trial of RIT in ovarian cancer. As regards the clinical results, the published outcome of various trials and the experience of the National Cancer Institute of Milan are summarized. Even if the number of patients involved in these clinical studies of RIT is too small to provide conclusive indications about its role in the management of ovarian cancer, the preliminary results from qualified groups show its potential in this disease despite the current problems that limit clinical application (above all, the instability of the radiolabeled linkage, the immunogenicity of murine antibodies, the poor absolute tumor radiolabel uptake and the bone marrow toxicity).

AB - Radioimmunotherapy (RIT) is a new therapeutical approach where radiolabeled monoclonal antibodies (M Ab) against tumor-associated antigens are administered to treat tumor lesions. Ovarian cancer is one of the most promising fields for RIT. This paper gives an overview of some biodistribution studies in animal models and in patients with radiolabeled anti-ovarian cancer M Abs, and defines the main criteria which should be considered to plan a clinical trial of RIT in ovarian cancer. As regards the clinical results, the published outcome of various trials and the experience of the National Cancer Institute of Milan are summarized. Even if the number of patients involved in these clinical studies of RIT is too small to provide conclusive indications about its role in the management of ovarian cancer, the preliminary results from qualified groups show its potential in this disease despite the current problems that limit clinical application (above all, the instability of the radiolabeled linkage, the immunogenicity of murine antibodies, the poor absolute tumor radiolabel uptake and the bone marrow toxicity).

UR - http://www.scopus.com/inward/record.url?scp=0027451773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027451773&partnerID=8YFLogxK

M3 - Article

C2 - 8277211

AN - SCOPUS:0027451773

VL - 8

SP - 187

EP - 191

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 3

ER -